WHO working group drafts resolution on SSFFC drugs

Published: 7-Nov-2011
Regulatory

Creates a mechanism for international collaboration among World Health Assembly members


The World Health Organization’s working group on low-quality and illegal medicines has drawn up a draft resolution for debate at the 65th World Health Assembly in May 2012.

The draft document backs the WHO’s role in ensuring the public’s access to safe, effective and affordable medicines of acceptable quality, but indicates that the agency should take a back seat on the topic of what have become known as substandard/spurious/falsely labelled/falsified/counterfeit (SSFFC) medical products.

The resolution would create a mechanism for international collaboration among World Health Assembly member states on the topic of SSFFCs to protect public health.

The WHO would continue to share information, create awareness, set standards and provide technical assistance to national governments.

The member state mechanism would identify major needs and challenges in the area of SSFFCs, make policy recommendations and develop tools for the prevention, detection and control of these products.

No progress has been made on finding a solution to the nomenclature of SSFFCs.

  • Companies:
  • World Health Organization
See more

You may also like

Personal Protection

Containment: key to tackling coronavirus outbreak

Read more
China and WHO authorities agreed that further studies on the severity and transmissibility of the virus are needed and immediate communication of any findings is crucial

Trending Articles

  1. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
  2. Isospec Analytics launches biomolecular analysis technology to identify unknown molecules The novel technology optimises the identification process of unknown molecules compared to mass analysis
  3. 4SC AG receives Paediatric Investigation Plan waiver for resminostat from the UK MHRA The waiver allows the company to avoid investigating the CTCL drug in a paediatric population, as it's considered unnecessary or inappropriate for use by this patient group
  4. Highly potent APIs: Hazards in classification and handling This variability and subjective nature of classification means that the OEL is best considered as a tool for site risk management teams
  5. Innovating with purpose for safety and security of outcome Beyond the importance of increasing productivity and generating more output and value with the same input, new ideas and technologies from GEA take innovation a step further

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Personal Protection

Containment: key to tackling coronavirus outbreak

China and WHO authorities agreed that further studies on the severity and transmissibility of the virus are needed and immediate communication of any findings is crucial
Regulatory

WHO proposes central registry on human genome editing research

On the heels of the Chinese CRISPR scandal, stakeholders in the genome editing industry will be consulted to create standards for future research
Regulatory

Annex 1 harmonisation moves a step closer

Revision to Annex 1 on the manufacturing of sterile medicinal products of the PIC/S – EU GMP Guide goes out for joint stakeholder consultation
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

EU considers endocrine disrupter controls

It has long been known that pharmaceutical residues can become hormone-affecting ‘endocrine disrupters’ when released into the environment and future controls are likely – but how will the legislators tackle the issue? Manufacturing Chemist reports
Regulatory

India Pharmacopoeia Commission joins WHO network

India has set up 179 centres to monitor adverse drug reactions across the country
Regulatory

European Commission, EMA and WHO step up co-operation to protect global public health

New working arrangement will allow timely sharing of non-public information
Regulatory

Vietnamese national regulatory authority meets international standards for vaccine regulation

The World Health Organisation has formally certified that Vietnam has a fully equipped national regulatory system that ensures the safety and efficacy of vaccines produced and used in the country
Subscribe now